Search Results - "Lutgens, Maurice W M D"

Risk Factors for Rectal Stump Cancer in Inflammatory Bowel Disease by Lutgens, Maurice W. M D, van Oijen, Martijn G H, Vleggaar, Frank P, Siersema, Peter D, Broekman, Mark M. T J, Oldenburg, Bas

“…BACKGROUND:Patients with long-standing colitis carry an increased risk of colorectal cancer and are therefore enrolled in colonoscopic surveillance programs…”
Get full text

Therapeutic drug monitoring of methotrexate in patients with Crohn's disease by van de Meeberg, Maartje M, Fidder, Herma H, Oldenburg, Bas, Sundaresan, Janani, Struys, Eduard A, Montazeri, Nahid S M, Mares, Wout G N, Mahmmod, Nofel, van Asseldonk, Dirk P, Lutgens, Maurice W M D, Kuyvenhoven, Johan P, Rietdijk, Svend T, Nissen, Loes H C, Koehestanie, Parweez, de Boer, Nanne K H, de Jonge, Robert, Bouma, Gerd, Bulatović Ćalasan, Maja

“…Therapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate-polyglutamate (MTX-PG) in…”
Get full text

Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis by Wijnands, Anouk M., de Jong, Michiel E., Lutgens, Maurice W.M.D., Hoentjen, Frank, Elias, Sjoerd G., Oldenburg, Bas

“…Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer (CRC). We performed a systematic review and meta-analysis to…”
Get full text

Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies by Lutgens, Maurice W M D, van Oijen, Martijn G H, van der Heijden, Geert J M G, Vleggaar, Frank P, Siersema, Peter D, Oldenburg, Bas

“…Recently reported risks of colorectal cancer (CRC) in inflammatory bowel disease (IBD) have been lower than those reported before 2000. The aim of this…”
Get full text

Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives by Wijnands, Anouk M., Mahmoud, Remi, Lutgens, Maurice W.M.D., Oldenburg, Bas

“…•Chronic inflammation predisposes patients with colonic IBD to develop CRC.•Surveillance enables early detection of dysplastic lesions and CRC.•Improved…”
Get full text

The Efficacy of an Over-the-Counter Multivitamin and Mineral Supplement to Prevent Infections in Patients With Inflammatory Bowel Disease in Remission With Immunomodulators and/or Biological Agents: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial by Laheij, Robin L H, van Knippenberg, Yara M W, Heil, Annelijn L J, Mannaerts, Britt J W, Bruin, Karlien F, Lutgens, Maurice W M D, Sikkema, Marjolein, de Wit, Ulrike, Laheij, Robert J F

“…Abstract Background Patients with inflammatory bowel disease (IBD) treated with immunomodulators or biologic therapy are at increased risk of infections…”
Get full text

Patients Prioritize a Low-volume Bowel Preparation in Colitis-associated Colorectal Cancer Surveillance: A Discrete Choice Experiment by Wijnands, Anouk M, te Groen, Maarten, Peters, Yonne, Kaptein, Ad A, Oldenburg, Bas, Hoentjen, Frank, Lutgens, Maurice W M D

“…Abstract Background Patients with inflammatory bowel disease (IBD) undergo surveillance colonoscopies at fixed intervals to reduce the risk of colorectal…”
Get full text

Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease by Mahmoud, Remi, Savelkoul, Edo H.J., Mares, Wout, Goetgebuer, Rogier, Witteman, Ben J.M., de Koning, Daan B., van Tuyl, Sebastiaan A.C., Minderhoud, Itta, Lutgens, Maurice W.M. D., Akol-Simsek, Dilek, van Schaik, Fiona D.M., Fidder, Herma H., Jansen, Jeroen M., van Boeckel, Petra G.A., Mahmmod, Nofel, Horjus-Talabur Horje, Carmen S., Römkens, Tessa E.H., Colombel, Jean-Frédéric, Hoentjen, Frank, Jharap, Bindia, Oldenburg, Bas

“…Discontinuation of anti–tumor necrosis factor-α treatment (anti-TNF) (infliximab and adalimumab) in patients with inflammatory bowel disease (IBD) is…”
Get full text

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease by Mahmmod, Shaden, Schultheiss, Johannes P D, van Bodegraven, Ad A, Dijkstra, Gerard, Gilissen, Lennard P L, Hoentjen, Frank, Lutgens, Maurice W M D, Mahmmod, Nofel, van der Meulen–de Jong, Andrea E, Smits, Lisa J T, Tan, Adriaan C I T L, Oldenburg, Bas, Fidder, Herma H

“…Abstract Background Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to…”
Get full text

Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease by Wijnands, Anouk M., Penning de Vries, Bas B.L., Lutgens, Maurice W.M.D., Bakhshi, Zeinab, Al Bakir, Ibrahim, Beaugerie, Laurent, Bernstein, Charles N., Chang-ho Choi, Ryan, Coelho-Prabhu, Nayantara, Graham, Trevor A., Hart, Ailsa L., ten Hove, Joren R., Itzkowitz, Steven H., Kirchgesner, Julien, Mooiweer, Erik, Shaffer, Seth R., Shah, Shailja C., Elias, Sjoerd G., Oldenburg, Bas, van Bodegraven, Adriaan A., Fidder, Herma H., Hirdes, Meike M.C., Hoentjen, Frank, Jansen, Jeroen M., Mahmmod, Nofel, van der Meulen-de Jong, Andrea E., Ponsioen, Cyriel Y., van Schaik, Fiona D.M., van der Woude, C. Janneke

“…Colonoscopic surveillance is recommended in patients with colonic inflammatory bowel disease (IBD) given their increased risk of colorectal cancer (CRC). We…”
Get full text

A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial by van Linschoten, Reinier C. A., Jansen, Fenna M., Pauwels, Renske W. M., Smits, Lisa J. T., Atsma, Femke, Kievit, Wietske, de Jong, Dirk J., de Vries, Annemarie C., Boekema, Paul J., West, Rachel L., Bodelier, Alexander G. L., Gisbertz, Ingrid A. M., Wolfhagen, Frank H. J., Römkens, Tessa E. H., Lutgens, Maurice W. M. D., van Bodegraven, Adriaan A., Oldenburg, Bas, Pierik, Marieke J., Russel, Maurice G. V. M., de Boer, Nanne K., Mallant-Hent, Rosalie C., ter Borg, Pieter C. J., van der Meulen-de Jong, Andrea E., Jansen, Jeroen M., Jansen, Sita V., Tan, Adrianus C. I. T. L., van der Woude, C. Janneke, Hoentjen, Frank

“…Background In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose intervals was…”
Get full text

Disease severity does not affect the interval between IBD diagnosis and the development of CRC: Results from two large, Dutch case series by Mooiweer, Erik, Baars, Judith E., Lutgens, Maurice W.M.D., Vleggaar, Frank, van Oijen, Martijn, Siersema, Peter D., Kuipers, Ernst J., der Woude, C. Janneke van, Oldenburg, Bas

“…The increased risk of colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD) is well established. The incidence of IBD-related CRC however,…”
Get full text

Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study by Derikx, Lauranne A A P, Lantinga, Marten A, de Jong, Dirk J, van Dop, Willemijn A, Creemers, Rob H, Römkens, Tessa E H, Jansen, Jeroen M, Mahmmod, Nofel, West, Rachel L, Tan, Adriaan C I T L, Bodelier, Alexander G L, Gorter, Moniek H P, Boekema, Paul J, Halet, Eric R C, Horjus, Carmen S, van Dijk, Maarten A, Hirdes, Meike M C, Epping Stippel, Ludger S M, Jharap, Bindia, Lutgens, Maurice W M D, Russel, Maurice G, Gilissen, Lennard P L, Nauta, Sjoukje, van Bodegraven, Adriaan A, Hoentjen, Frank

“…Abstract Background and Aims The COVID-19 risk and disease course in inflammatory bowel disease [IBD] patients remains uncertain. Therefore, we aimed to assess…”
Get full text

Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease by Crouwel, Femke, Simsek, Melek, de Boer, Marjon A, Mulder, Chris J J, van Andel, Emma M, Creemers, Rob H, van Asseldonk, Dirk P, van Bodegraven, Ad A, Horjus, Carmen S, Visschedijk, Marijn C, Weusthuis, Angelique L M, Seinen, Margien L, Jharap, Bindia, van Schaik, Fiona D M, Ahmad, Ishfaq, Boekema, Paul J, Tack, Greetje J, Wormmeester, Louktje, Lutgens, Maurice W M D, van Boeckel, Petra G A, Gilissen, Lennard P L, Kerkhof, Marjon, Russel, Maurice G V M, Hoentjen, Frank, Bartelink, Maartje E, Kuijvenhoven, Johan P, Maljaars, Jeroen W J, van Dop, Willemijn A, Wonders, Janneke, van der Voorn, Michael M P J A, Buiter, Hans J C, de Boer, Nanne K

“…Abstract Background Safety of thioguanine in pregnant patients with inflammatory bowel disease [IBD] is sparsely recorded. This study was aimed to document the…”
Get full text

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial by Jansen, Fenna M, van Linschoten, Reinier C A, Kievit, Wietske, Smits, Lisa J T, Pauwels, Renske W M, de Jong, Dirk J, de Vries, Annemarie C, Boekema, Paul J, West, Rachel L, Bodelier, Alexander G L, Gisbertz, Ingrid A M, Wolfhagen, Frank H J, Römkens, Tessa E H, Lutgens, Maurice W M D, van Bodegraven, Adriaan A, Oldenburg, Bas, Pierik, Marieke J, Russel, Maurice G V M, de Boer, Nanne K, Mallant-Hent, Rosalie C, ter Borg, Pieter C J, van der Meulen-de Jong, Andrea E, Jansen, Jeroen M, Jansen, Sita V, Tan, Adrianus C I T L, Hoentjen, Frank, van der Woude, C Janneke

“…Abstract Background and Aims We aimed to assess cost-effectiveness of increasing adalimumab dose intervals compared to the conventional dosing interval in…”
Get full text

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial by van Linschoten, Reinier C A, Jansen, Fenna M, Pauwels, Renske W M, Smits, Lisa J T, Atsma, Femke, Kievit, Wietske, de Jong, Dirk J, de Vries, Annemarie C, Boekema, Paul J, West, Rachel L, Bodelier, Alexander G L, Gisbertz, Ingrid A M, Wolfhagen, Frank H J, Römkens, Tessa E H, Lutgens, Maurice W M D, van Bodegraven, Adriaan A, Oldenburg, Bas, Pierik, Marieke J, Russel, Maurice G V M, de Boer, Nanne K, Mallant-Hent, Rosalie C, Ter Borg, Pieter C J, van der Meulen-de Jong, Andrea E, Jansen, Jeroen M, Jansen, Sita V, Tan, Adrianus C I T L, van der Woude, C Janneke, Hoentjen, Frank

“…Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to…”
Get more information

Easily obtainable clinical features increase the diagnostic accuracy for latent autoimmune diabetes in adults: An evidence-based report by Lutgens, Maurice W.M.D, Meijer, Melanie, Peeters, Babette, Poulsen, Marie-Louise N.F, Rutten, Marjet J, Bots, Michiel L, van der Heijden, Geert J.M.G, Soedamah-Muthu, Sabita S

“…Abstract Background Latent autoimmune diabetes in adults (LADA) represents a subgroup of diabetes mellitus. LADA is characterised by adult-onset diabetes and…”
Get full text